Introduction
Acute promyelocytic leukemia (APL) is a discrete subtype of acute myeloid leukemia (AML) characterized by a t(15;17) translocation, rearrangement of the PML and RARA genes, and formation of an abnormal chimeric retinoic acid receptor transcription factor (PML-RARα) (1) .
The latter disrupts normal myeloid differentiation programs, but at the same time imparts a unique sensitivity on APL cells to pharmacological doses of all-trans-retinoic acid (ATRA) (2) , such that it is now an indispensable component of anti-leukemic therapy in APL. The combination of ATRA with chemotherapy has achieved remarkable improvements in the long-term outcome of patients with APL (3) (4) (5) (6) , but precisely what constitutes optimal chemotherapy remains contentious. While it has been argued that outcomes are not improved by the addition of multiple chemotherapy agents to a combination of idarubicin and mitoxantrone (7) , comparison of the European APL2000 and the PETHEMA LPA99 protocols suggests that patients with a white cell count (WCC) ≥ 10 x 10 9 /L may benefit when cytarabine is added to daunorubicin during induction and consolidation (8) .
In 1997, the Australasian Leukaemia and Lymphoma Group (ALLG) initiated the APML3 protocol which utilised GIMEMA-style induction with ATRA and 4 doses of idarubicin (based on the AIDA0493 protocol(4)), but the protocols differed in their approach to consolidation.
Whereas the AIDA protocol incorporated varying combinations of idarubicin, cytarabine, mitoxantrone, etoposide and 6-thioguanine in 3 consolidation cycles, the ALLG exploited the perceived superiority of anthracyclines over other chemotherapeutic agents in APL by employing another 4 doses of idarubicin in one chemotherapy consolidation cycle. In order to further reduce minimal residual disease(9) without inducing resistance (10) , additional ATRA was then administered on an intermittent basis in three 2-week cycles for all patients in hematological remission. The initial protocol involved regular molecular monitoring without further therapy, but it was subsequently amended to include 2 years of triple maintenance with ATRA, methotrexate (MTX) and 6-mercaptopurine (6MP) following the demonstrated benefit of this approach in the European APL93 trial (11) . In this report we describe mature outcome data for the ALLG APML3 trial, with particular emphasis on (i) the prognostic -5 -significance of pre-treatment variables, (ii) the anti-leukemic activity of only two cycles of idarubicin in combination with ATRA, and (iii) the impact of maintenance therapy on remission duration. Quantitation of PML-RARA transcripts was also performed retrospectively on archival diagnostic RNA samples using a one-step, RT-PCR DNAzyme-mediated reaction (14) .
Design and methods

Eligibility
FLT3 mutational status
Expression of mutant FLT3 transcripts was assessed for both internal tandem duplications before completion of the third cycle of iATRA due to failure to achieve remission, excessive toxicity, or patient refusal.
Statistical methods
Categorical factors at baseline that were investigated for their prognostic value included WCC, platelet count, Sanz risk stratification (7), PML breakpoint (bcr1 versus bcr2 versus bcr3), and FLT3 status (wildtype versus ITD and/or codon 835/836 mutations). Continuousscale factors included age and log-transformed normalised PML-RARA transcripts. A maintenance-cohort factor which indexed patients according to whether they were registered before or after activation of the maintenance amendment enabled an intention-to-treat (ITT)
analysis of post-remission maintenance as a prognostic factor. Given that some patients who were registered prior to the amendment did receive maintenance, and some patients registered after the amendment did not, analysis of the association of actual post-remission maintenance with survival was also conducted; in the latter analysis separate indicator variables for ATRA, 6MP and MTX maintenance administration in each 3-month period after consolidation were included as time-dependent covariates.
The association of baseline prognostic variables with both the incidence of early death and the achievement of CR were investigated using binary logistic regression. For time-to-event endpoints of survival and duration, unifactor associations of categorical prognostic factors -9 - were investigated with the log-rank test while unifactor associations of continuous-scale covariates and all multifactor analyses were investigated via Cox proportional hazards regression and the score test. Competing events, such as relapse and death in CR, were analysed by estimating cumulative incidences using a competing risks analysis. Unless otherwise stated, all statistical tests were two-tailed tests without adjustment for multiple comparisons, and were carried out using SAS (Version 9.2) and S-Plus software.
Results
Patient characteristics
Of 107 registered patients, 6 were excluded because of failure to demonstrate either t (15;17) or PML-RARA transcripts at diagnosis, leaving 101 patients from 26 institutions in Australia and New Zealand eligible for analysis of both efficacy and toxicity ( (Table 2) . FLT3 mutation positive patients, especially those with ITDs, were more likely to have a WCC > 10 x 10 9 /L (p < 0.0001) and a bcr3 PML breakpoint (p < 0.0001).
Early deaths
Eight patients (8%) died within 30 days of study entry. Causes of death were usually multifactorial, and included hemorrhage (7 patients, with 4 intracerebral, 2 pulmonary, and 1 gastrointestinal), DS (4 patients), sepsis (3 patients), multi-organ failure (3 patients), and necrotizing enteritis (1 patient). DS was a major contributing factor in the deaths of 2 patients. The WCC at diagnosis was strongly associated with an increased risk of early death, with a cutoff of 2.5 x 10 9 /L being the most discriminatory; no early deaths occurred amongst the 55 patients (0%) with WCC ≤ 2.5 x 10 9 /L, whereas 8 of 46 patients (17%) with WCC > 2.5 x 10 9 /L died within 30 days (p < 0.002). The platelet count at diagnosis, age, and -10 -FLT3 mutations were not associated with early death, nor was WCC at diagnosis when a cutoff of 10 x 10 9 /L was used.
Remission (i) Hematologic CR
Of 93 patients who survived more than 30 days, 2 were taken off study because of failure to achieve hematologic CR. One patient was withdrawn prematurely at day 18 because of persistent disseminated intravascular coagulation; a progress marrow aspirate showed 11%
blasts and 38% promyelocytes, with 100% abnormal metaphases. The other patient was assessed at day 36; a marrow aspirate produced only a blood tap, but contained numerous abnormal promyelocytes. Cytogenetics showed 60% abnormal metaphases, and interphase (
ii) Molecular CR
After the first cycle of idarubicin, molecular results for PML-RARA were available for 79 patients (including the 2 who were withdrawn because of persistent leukemia). Only 24 were negative (molecular CR rate 30%, 95% CI ± 10.1%). After the second cycle of chemotherapy, 69 of 74 patients tested had achieved molecular CR (93%, 95% CI ± 5.7%).
Of the 85 patients who completed 3 cycles of iATRA, all of the 81 patients tested were RT-PCR negative (molecular CR 100%); the 4 patients not tested were already in molecular remission before commencing iATRA. Thus there was no evidence of minimal residual disease in patients who completed induction and consolidation therapy. Figure 1A) . None of the remaining prognostic factors was statistically significant; however an increase in the risk of relapse in patients with a bcr2 PML breakpoint relative to bcr1 was observed (Table 3) .
Eighty-five of the 91 patients who achieved CR completed three cycles of iATRA within 145 to 230 days from the time treatment commenced. Accordingly, a landmark analysis of RD restricted to these 85 patients, and measured from day 231, was also performed. Both the ITT maintenance factor (HR=0.296, 95% CI: 0.132-0.665, p=0.003), and the treating hematologist's determination of whether CR was achieved after the first or second cycle of idarubicin (HR=2.581, 95% CI: 1.097-6.075, p=0.030), were statistically significantly associated with RD in multifactor analysis (Table 3 and Figure 1B ).
Survival (i) Disease free survival
In addition to the 25 relapses, 2 patients died in CR as a result of complications of the second cycle of idarubicin (one from suspected cardiac arrhythmia, one with intracerebral fungal infection and hemorrhage). Estimated 4-year DFS was 69.7% (95% CI: 58.9% -78.1%). Multifactor analysis indicated that ITT maintenance cohort was the only statistically significant prognostic factor associated with DFS (HR = 0.290, 95% CI: 0.136 -0.620, -12 -p < 0.001, 4-year DFS: 46.9% vs. 78.9%, Table 3 ). In addition, DFS was reduced in patients with a bcr2 PML breakpoint relative to bcr1 (Table 3) .
(ii) Overall survival
Prior to the close-out date there were a total of 16 deaths (8 early deaths, 2 deaths in CR, 5 patients died after relapsing, and 1 patient was withdrawn from the study after induction because of resistant leukemia and died during salvage therapy considering time-dependent maintenance covariates is shown in Table 4 . In comparison with Table 3 , FLT3 mutation status and PML bcr2 breakpoint location are additional prognostic factors statistically significantly associated with RD and DFS. As the number of patients with bcr2 breakpoints was small, the relevance of this latter observation is uncertain.
Discussion
The APML3 protocol accrued patients between 1997 and 2002. Our strategy of utilising idarubicin as the only chemotherapy agent for both induction and consolidation most closely resembles the PETHEMA group's approach, as typified by LPA96 and LPA99 (16) . These PETHEMA protocols were modelled on the GIMEMA AIDA0493 protocol (4) , and that strategy was associated with a significant improvement in overall CIR (11% at 4 years) (17) .
At the time APML3 was initiated, the benefits of maintenance therapy had not been demonstrated in a randomized fashion, and hence maintenance was not originally included.
However the clear benefits of maintenance reported in the European APL93 study (11) , and in the North American Intergroup APL protocol (19) , persuaded the ALLG to amend APML3 in an attempt to reduce what was emerging as an unacceptably high relapse rate. The two approaches examining the impact of maintenance in APML3 that are reported here (an ITT -14 - analysis and an exploratory analysis in which actual post-remission maintenance components were treated as time-dependent covariates) both demonstrate a statistically significant improvement in RD, DFS and FFS, in both univariate and multivariate analysis. In contrast to the European APL93 and the North American Intergroup randomized studies, the GIMEMA AIDA0493 study failed to show an improvement associated with maintenance (20) , and that difference has been attributed to the more intensive chemotherapy employed in the AIDA0493 study. Since APML3 also utilised less total chemotherapy than AIDA0493, it is not surprising that maintenance had a significant effect on the APML3 relapse rate.
The adverse prognostic impact of FLT3 mutations in non-APL AML is well documented (21) (22) (23) (24) , especially in the context of normal karyotype AML. In APL, data supporting an adverse impact of FLT3 mutations are less consistent (25) (26) (27) (28) (29) (30) , despite their high prevalence. In the present study, as with previous reports, FLT3 mutations are closely correlated with bcr3 breakpoints and high WCC at diagnosis. We found a significant correlation with OS, and that association persisted when ITDs and codon 835/836 mutations were assessed separately.
FLT3 mutations also emerged as important predictors of RD and DFS in multivariate analyses when maintenance components were treated as time-dependent covariates. Our data are in close agreement with a large meta-analysis(29) of FLT3 mutations in 1063 APL patients. In that analysis, FLT3 ITD were significantly associated with both OS and DFS, and a trend towards adverse outcomes was also observed for patients with codon 835 mutations (although only two studies reported codon 835 data). A subsequent report (30) of FLT3 mutations in the PETHEMA group's LPA96 and LPA99 trials also showed inferior overall and relapse free survival for patients with ITDs in univariate analysis, but ITDs were not significant in multivariate analysis due to their close relationship with high WCC. However, the PETHEMA report included ITD and codon 835 data for only 41% and 29% of the patients respectively. Although the number of patients in the present report is relatively small, FLT3 mutation data were available for 89% of the study population, and therefore selection bias is unlikely to be a factor in the adverse impact of FLT3 mutations that we observed. Whether the addition of FLT3 inhibitors would influence outcomes is unknown, especially as the -15 -adverse impact of FLT3 mutations are less likely to be apparent when protocols which employ more intensive chemotherapy or arsenic trioxide (ATO) are used.
The 2009 European LeukemiaNet guidelines for APL(31) do not recommend cytogenetic or molecular analysis for determination of response after induction, and caution against morphological diagnosis of incomplete remission due to delayed maturation because virtually all patients treated with AIDA-style induction protocols eventually achieve CR. Two patients in the current study were withdrawn because of "failure to achieve CR", and with the benefit of hindsight those withdrawals were probably inappropriate. Similarly, those patients who were deemed not to have achieved morphological CR after the first cycle of idarubicin may have been assessed prematurely, since they all achieved molecular CR by the end of consolidation, consistent with the European LeukemiaNet recommendations. Nevertheless, our observation of a shorter remission duration in these patients based on a landmark analysis at the end of consolidation is of interest, since it highlights a potentially important difference in long-term outcome in patients with delayed maturation, and indirectly suggests that more effective induction regimens that achieve a greater degree of early leukemic cytoreduction might be associated with better relapse free survival.
In summary, the APML3 protocol shows that an induction and consolidation strategy that combines ATRA with relatively low anthracycline exposure (delivered in only 2 chemotherapy cycles), followed by 2 years of triple maintenance, is capable of achieving prolonged DFS in the majority of patients. However, high risk subgroups (eg. patients with FLT3 mutations and/or high WCC) require either more intensive therapy (17) , or therapy with alternative antileukemic agents such as arsenic trioxide (ATO) (32, 33) . The recently completed ALLG APML4 protocol has combined ATO with ATRA and idarubicin for induction, and uses only ATRA and ATO without further anthracycline for consolidation (total idarubicin exposure only 48mg/m 2 ). Preliminary data indicate this strategy has been highly successful in reducing relapses and improving long-term disease free survival(34, and manuscript in preparation).
- 19 - * As there were no deaths in patients with bcr2 breakpoints, the hazard ratio and confidence intervals cannot be adequately defined. 
